Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425538 | 0.99 | VIPR2 (0.51) | VIPR2VIPR1F2BACE1IL23R | |
| SCHEMBL30362779 | 0.97 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1IL23R | |
| SCHEMBL30543189 | 0.97 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1IL23R | |
| SCHEMBL30741250 | 0.93 | VIPR2 (0.56) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29466598 | 0.90 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30798736 | 0.88 | F2 (0.53) | VIPR2VIPR1F2NTSR2NTSR1 | |
| SCHEMBL29520980 | 0.88 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29778027 | 0.88 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30107616 | 0.87 | F2 (0.49) | VIPR2VIPR1F2BACE1IL23R | |
| SCHEMBL29679828 | 0.85 | F2 (0.52) | VIPR2VIPR1F2IL23RNTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230670-B | Chimeric Antigen Receptor (CAR) targeting hematological malignancies, compositions and methods of use thereof | 美商生物细胞基因治疗有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-114720356-B | Flow cytometry detection kit for advanced immune characterization of lung cancer and detection method thereof | 李太生 | 2025-05-13 | — | — | CN | disclosed |
| US-20240238428-A1 | TARGETED SELENIUM CONJUGATES AS COUNTERMEASURES FOR VIRAL AND CELLULAR PATHOGENS | TEXAS TECH UNIVERSITY SYSTEM | 2024-07-18 | — | — | US | disclosed |
| EP-4337957-A1 | TARGETED SELENIUM CONJUGATES AS COUNTERMEASURES FOR PATHOGENIC VIRUSES AND CELLS | Texas Tech University System (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-112088008-B | Expansion of modified cells and uses thereof | 浙江煦顼技术有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-115916833-B | Antigen binding polypeptide targeting B7H3 and application thereof | 宁波茂行生物医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-115103633-B | Imaging method using multiple imaging agents | 伊麦吉纳博公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-114163534-B | Bispecific chimeric antigen receptor targeting HIV-1 virus envelope protein and preparation method and application thereof | 复旦大学 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022240936-A1 | TARGETED SELENIUM CONJUGATES AS COUNTERMEASURES FOR PATHOGENIC VIRUSES AND CELLS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115103633-A | Imaging method using multiple imaging agents | 伊麦吉纳博公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-110257338-B | Chimeric cytokine receptors | 上海斯丹赛生物技术有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114773486-A | Immunomodulatory proteins with tunable affinity | 高山免疫科学股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114761802-A | Method for identifying T cell receptor | 大学健康网络 | 2022-07-15 | — | — | CN | disclosed |
| CN-114720356-A | Flow cytometry detection kit for lung cancer late stage immune characterization and detection method thereof | 李太生 | 2022-07-08 | — | — | CN | disclosed |
| CN-112175087-B | Bispecific antibody for resisting CD4 and TGF beta, pharmaceutical composition and application thereof | 深圳市迈加瑞生物技术有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114450303-A | MHC class II molecules and methods of use thereof | 大学健康网络 | 2022-05-06 | — | — | CN | disclosed |
| CN-112500491-B | Bispecific antibody for specifically neutralizing helper T cell TGF-beta signal, pharmaceutical composition and application thereof | 深圳市迈加瑞生物技术有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114230670-A | Chimeric Antigen Receptors (CARs) targeting hematologic malignancies, compositions thereof, and methods of use | 美商生物细胞基因治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238428-A1 | TARGETED SELENIUM CONJUGATES AS COUNTERMEASURES FOR VIRAL AND CELLULAR PATHOGENS | GPX1, GPX4, SCLY | VIPR2 4270/4885VIPR1 3075/4885F2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.